You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK-positive NSCLC

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ALK-positive NSCLC Trial in Jilin (XZP-3621)

Not yet recruiting
  • ALK-positive NSCLC
  • Jilin, Chang Chun, China
    Jilin Province Cancer Hospital
Jul 29, 2022

Non-small-cell Lung Carcinoma Trial in Beijing (SY-3505)

Recruiting
  • Non-small-cell Lung Carcinoma
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
May 11, 2023

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • Beijing, Beijing, China
    Department of Respiratory and Critical Care Medicine, Peking Uni
Aug 10, 2022

Non Small Cell Lung Cancer Trial in Goyang-si (Brigatinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Goyang-si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer

Active, not recruiting
  • Non-Small-Cell Lung Carcinoma
  • New York, New York
    Pfizer Inc
Apr 12, 2022

NSCLC Stage IV, ALK Fusion Protein Expression Trial (Peptide vaccine)

Not yet recruiting
  • NSCLC Stage IV
  • ALK Fusion Protein Expression
  • Peptide vaccine
  • (no location specified)
Jul 21, 2023

Iruplinalkib in Treatment of ALK-Positive Non-Small Cell Lung

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Aug 8, 2023

NSCLC Trial in Shanghai (WX-0593)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, China
    Shanghai Jiao Tong University Chest Hospital
Mar 24, 2023

ALK Positive NSCLC Trial in Guangzhou (Loratinib)

Recruiting
  • ALK Positive Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial Perople's Hospital
Oct 19, 2023

NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

Not yet recruiting
  • Non-Small Cell Lung Cancer(NSCLC)
  • WX-0593 Tablets
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Mar 1, 2023

Lung Cancer, NSCLC Trial (Lorlatinib, Cisplatin or Carboplatin, Pemetrexed)

Not yet recruiting
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • (no location specified)
Jul 7, 2023

NSCLC Trial in Davis, San Francisco (Ceritinib, Trametinib)

Terminated
  • Non-small Cell Lung Cancer
  • Davis, California
  • +1 more
Dec 22, 2022

Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese

Completed
  • ALK-positive Non-small-cell Lung Cancer
  • Nagoya, Aichi, Japan
  • +15 more
Jan 31, 2022

NSCLC Trial in Guangzhou (Ensartinib, Bevacizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Aug 4, 2022

free Survival and Evaluate Participant Experience for Metastatic

Active, not recruiting
  • Anaplastic Lymphoma Kinase-positive
  • Carcinoma Non-small-cell Lung
  • Maynard, Massachusetts
    EmpiraMed, Inc.
Feb 28, 2022

Non Small Cell Lung Cancer Trial (TGRX-326, Crizotinib)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • (no location specified)
Oct 8, 2023

Information Available in Chinese Non-Small-cell Lung Cancer

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Shanghai, Shanghai, China
    Department of Oncology, Shanghai pulmonary hospital
Feb 1, 2023

NSCLC, ALK Gene Rearrangement Positive Trial in United States (Ensartinib)

Available
  • Non-Small Cell Lung Cancer
  • ALK Gene Rearrangement Positive
  • Stanford, California
  • +3 more
Oct 18, 2022

Ensatinib in alK-positive Patients Undergoing Initial Treatment

Recruiting
  • ALK Positive
  • +2 more
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 16, 2021

NSCLC Trial in Germany (Brigatinib, Tyrosine kinase inhibitor)

Recruiting
  • NSCLC
  • Berlin, Germany
  • +25 more
Nov 10, 2022

NSCLC Trial in Guangzhou (TGRX-326)

Recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jun 29, 2022

PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

Recruiting
  • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 9, 2022

    ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Tumor of Lung Trial in Mexico City (Alectinib, Bevacizumab)

    Unknown status
    • ALK Gene Rearrangement Positive
    • Non-Squamous Non-Small Cell Neoplasm of Lung
    • Mexico City, Mexico
      Instituto Nacional de Cancerologia
    Feb 8, 2021

    Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

    Recruiting
    • Nsclc
    • +5 more
    • Hong Kong, Hong Kong
      Queen Mary Hospital
    Nov 25, 2021